RXRα deletion and E6E7 oncogene expression are sufficient to induce cervical malignant lesions in vivo

Cancer Letters

Volumn 317, Issue 2, 2012, Pages 226-236

  Ocadiz Delgado, Rodolfo ^a,b   Castañeda Saucedo, Eduardo ^c   Indra, Arup K ^c,g   Hernandez Pando, Rogelio ^d   Flores Guizar, Pedro ^a   Cruz Colin, Jose Luis ^a   Recillas Targa, Felix ^e   Perez Ishiwara, Guillermo ^b   Covarrubias, Luis ^f   Gariglio, Patricio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSERM   (France)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cervical cancer; E6E7; HPV; Murine models; Retinoid receptor

Indexed keywords

MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAX GENE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; E6E7 GENE; FEMALE; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC RECOMBINATION; GENETIC VARIABILITY; HUMAN PAPILLOMAVIRUS TYPE 16; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; P21WAF1 GENE; PRIORITY JOURNAL; PROTO ONCOGENE; RETINOID X RECEPTOR ALPHA GENE; TRANSGENE; TUMOR GENE; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CERVIX UTERI; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, GENETIC; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; REPRESSOR PROTEINS; RETINOID X RECEPTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; MURINAE; PAPILLOMAVIRIDAE;

EID: 84856606248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.031     Document Type: Article

References (92)

1. zur Hausen H. Papillomavirus infections: a major cause of human cancer. Biochim. Biophys. Acta 1996, 1288:F55-F78.
2. zur Hausen H. The search for infectious causes of human cancers: where and why (Nobel lecture). Angew Chem. Int. Ed. Engl. 2009, 48:5798-5808.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosh F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
4. Sankaranarayanan R., Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best. Pract. Res. Clin. Obstet. Gynaecol. 2006, 20:207-225.
5. McLaughlin-Drubin M.E., Münger K. Oncogenic activities of human papillomaviruses. Virus Res. 2009, 143:195-208.
6. Moscicki A.B. Impact of HPV infection in adolescent populations. J. Adolesc. Health 2005, 37:S3-S9.
7. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55:244-265.
8. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
9. Woodworth C.D., Doniger J., DiPaolo J.A. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J. Virol. 1989, 63:159-164.
10. Van den Brule A.J., Cromme F.V., Snijders P.J., Smit L., Oudejans C.B., Baak J.P., Meijer C.J., Walboomers J.M. Nonradioactive RNA in situ hybridization detection of human papillomavirus 16-E7 transcripts in squamous cell carcinomas of the uterine cervix using confocal laser scan microscopy. Am. J. Pathol. 1991, 139:1037-1045.
11. Bedell M.A., Jones K.H., Grossman S.R., Laimins L.A. Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J. Virol. 1989, 63:1247-1255.
12. Phelps W.C., Yee C.L., Münger K., Howley P.M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988, 53:539-547.
13. Storey A., Pim D., Murray A., Osborn K., Banks L., Crawford L. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 1988, 7:1815-1820.
14. Storey A., Banks L. Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene 1993, 8:919-924.
15. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
16. Nicol A.F., Nuovo G.J., Dillner J. A summary of the 25th International Papillomavirus Conference 2009: vaccines, screening, epidemiology and therapeutics. J. Clin. Virol. 2010, 47:208-215.
17. Lagunas-Martínez M., Madrid-Marina V., Gariglio P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim. Biophys. Acta 2010, 1805:6-16.
18. Shin M.K., Balsitis S., Brake T., Lambert P.F. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 2009, 69:5656-5663.
19. Tungteakkhun S.S., Duerksen-Hughes P.J. Cellular binding partners of the human papillomavirus E6 protein. Arch. Virol. 2008, 153:397-408.
20. Valencia C., Bonilla-Delgado J., Oktaba K., Ocadiz-Delgado R., Gariglio P., Covarrubias L. Human papillomavirus E6/E7 oncogenes promote mouse ear regeneration by increasing the rate of wound re-epithelization and epidermal growth. J. Invest. Dermatol. 2008, 128:2894-2903.
21. Eckert R.L., Crish J.F., Balasubramanian S., Rorke E.A. Transgenic animal models of human papillomavirus-dependent disease. Int. J. Oncol. 2000, 16:853-870.
22. Wolf J.K., Franco E.L., Arbeit J.M., Shroyer K.R., Wu T.C., Runowicz C.D., Tortolero-Luna G., Herrero R., Crum C.P. Innovations in understanding the biology of cervical cancer. Cancer 2003, 98:2064-2069.
23. Chung S.H., Lambert P.F. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc. Natl. Acad. Sci. USA 2009, 106:19467-19472.
24. Jabbar S.F., Abrams L., Glick A., Lambert P.F. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009, 69:4407-4414.
25. Shai A., Pitot H.C., Lambert P.F. E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res. 2010, 70:5064-5073.
26. Castellsagué X., Muñoz N. Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J. Natl. Cancer Inst. Monogr. 2003, 31:20-28. Chapter 3.
27. Muñoz N., Castellsagué X., de González A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24:S3/1-10. Chapter 1.
28. Huh W.K. Human papillomavirus infection: a concise review of natural history. Obstet. Gynecol. 2009, 114:139-143.
29. Gariglio P., Gutiérrez J., Cortés E., Vázquez J. The role of retinoid deficiency and estrogens as cofactors in cervical cancer. Arch. Med. Res. 2009, 40:449-465.
30. Abu J., Batuwangala M., Herbert K., Symonds P. Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol. 2005, 6:712-720.
31. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., Gronemeyer H. International union of pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev. 2006, 58:712-725.
32. Soprano D.R., Teets B.W., Soprano K.J. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitam. Horm. 2007, 75:69-95.
33. Mongan N.P., Gudas L.J. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 2007, 75:853-870.
34. Indra A.K., Warot X., Brocard J., Bornert J.M., Xiao J.H., Chambon P., Metzger D. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res. 1999, 27:4324-4327.
35. Metzger D., Indra A.K., Li M., Chapellier B., Calleja C., Ghyselinck N.B., Chambon P. Targeted conditional somatic mutagenesis in the mouse: temporally-controlled knock out of retinoid receptors in epidermal keratinocytes. Methods Enzymol. 2003, 364:379-408.
36. Li M., Indra A.K., Warot X., Brocard J., Messaddeq N., Kato S., Metzger D., Chambon P. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000, 407:633-636.
37. Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W., Desvergne B., Metzger D., Chambon P. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. J. Invest. Dermatol. 2007, 127:1250-1260.
38. Ocadiz-Delgado R., Castaneda-Saucedo E., Indra A.K., Hernandez-Pando R., Gariglio P. Impaired cervical homeostasis upon selective ablation of RXRalpha in epithelial cells. Genesis 2008, 46:19-28.
39. Escalante-Alcalde D., Recillas-Targa F., Valencia C., Santa-Olalla J., Chávez P., Marroquín A., Gutiérrez X., Gariglio P., Covarrubias L. Expression of E6 and E7 papillomavirus oncogenes in the outer root sheath of hair follicles extends the growth phase and bypasses resting at telogen. Cell Growth Differ. 2000, 11:527-539.
40. Ocadiz-Delgado R., Marroquin-Chavira A., Hernandez-Mote R., Valencia C., Manjarrez-Zavala M.E., Covarrubias L., Gariglio P. Induction of focal epithelial hyperplasia in tongue of young bk6-E6/E7 HPV16 transgenic mice. Transgenic Res. 2009, 18:513-527.
41. Schuler M., Dierich A., Chambon P., Metzger D. Efficient temporally controlled targeted somatic mutagenesis in hepatocytes of the mouse. Genesis 2004, 39:167-172.
42. Li M., Chiba H., Warot X., Messaddeq N., Gerard C., Chambon P., Metzger D. RXR-alpha ablation in skin keratinocytes results in alopecia and epidermal alterations. Development 2001, 128:675-688.
43. Brocard J., Warot X., Wendling O., Messaddeq N., Vonesch J.L., Chambon P., Metzger D. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc. Natl. Acad. Sci. USA 1997, 94:14559-14563.
44. Feil R., Brocard J., Mascrez B., LeMeur M., Metzger D., Chambon P. Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. USA 1996, 93:10887-10890.
45. Fujinaga Y., Shimada M., Okazawa K., Fukushima M., Kato I., Fujinaga K. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J. Gen. Virol. 1991, 72:1039-1044.
46. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
47. Riley R., Duensing S., Brake T., Münger K., Lambert P.F., Arbeit J.M. Dissection of Human Papillomavirus E6 and E7 Function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003, 63:4862-4871.
48. Whitten W.K. Occurrence of anoestrus in mice caged in groups. J. Endocrinol. 1959, 18:102-107.
49. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992, 119:493-501.
50. Nuovo G.J. Co-labeling using in situ PCR: a review. J. Histochem. Cytochem. 2001, 49:1329-1339.
51. Kellendonk F., Tronche F., Casanova E., Anlag K., Opherk C., Schutz G. Inducible site-specific recombination in the brain. J. Mol. Biol. 1999, 285:175-182.
52. Schwenk F., Kuhn R., Angrand P.O., Rajewsky K., Stewart A.F. Temporally and spatially regulated somatic mutagenesis in mice. Nucl. Acids Res. 1998, 26:1427-1432.
53. Tannour-Louet M., Porteu A., Vaulont S., Kahn A., Vasseur-Cognet M. A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology 2002, 35:1072-1081.
54. Juric D., Mahovlić V., Rajhvajn S., Ovanin-Rakić A., Skopljanac-Macina L., Barisić A., Projić I.S., Babić D., Susa M., Corusić A., Oresković S. Liquid-based cytology-new possibilities in the diagnosis of cervical lesions. Coll. Antropol. 2010, 34:19-24.
55. Bergeron C., Ordi J., Schmidt D., Trunk M.J., Keller T., Ridder R. European CINtec histology study group, conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol. 2010, 133:395-406.
56. Simoni D., Tolomeo M. Retinoids, apoptosis and cancer. Curr. Pharm. Des. 2001, 17:1823-1837.
57. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997, 11:2090-20100.
58. Jones D.L., Alani R.M., Münger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997, 11:2101-2111.
59. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
60. Liu H., Zang C., Fenner M.H., Liu D., Possinger K., Koeffler H.P., Elstner E. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 2006, 107:3683-3692.
61. Liu H.C., Chen G.G., Vlantis A.C., Tse G.M., Chan A.T., van Hasselt C.A. Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16. J Cell Biochem. 2008, 103:1125-1143.
62. Haldar S., Basu A., Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997, 57:229-233.
63. Chittenden T., Harrington E.A., O'Connor R., Flemington C., Lutz R.J., Evan G.I., Guild B.C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995, 374:733-736.
64. Graupner V., Alexander E., Overkamp T., Rothfuss O., De Laurenzi V., Gillissen B.F., Daniel P.T., Schulze-Osthoff K., Essmann F. Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level. Cell Death Differ. 2011, 18:1130-1139.
65. Nair P., Nair K.M., Jayaprakash P.G., Pillai M.R. Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. Pathol. Oncol. Res. 1999, 5:95-103.
66. Aguilar-Lemarroy A., Gariglio P., Whitaker N.J., Eichhorst S.T., zur Hausen H., Krammer P.H., Rösl F. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002, 21:165-175.
67. Aguilar-Lemarroy A., Kirchhoff S., Whitaker N., Gariglio P., zur Hausen H., Krammer P.H., Rösl F. Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis. Int. J. Cancer 2001, 93:823-831.
68. Chakrabarti O., Krishna S. Molecular interactions of ''high risk'' human papillomaviruses E6 and E7 oncoproteins: Implications for tumour progression. J. Biosci. 2003, 28:337-348.
69. Asadurian Y., Kurilin H., Lichtig H., Jackman A., Gonen P., Tommasino M., Zehbe I., Sherman L. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J. Med. Virol. 2007, 79:1751-1760.
70. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
71. Sedman S.A., Hubbert N.L., Vass W.C., Lowy D.R., Schiller J.C. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated transactivation or transforming activity. J. Virol. 1992, 66:4201-4208.
72. Pan H., Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev. 1995, 9:2157-2169.
73. Magal S.S., Jackman A., Ish-Shalom S., Botzer L.E., Gonen P., Schlegel R., Sherman L. Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J. Gen. Virol. 2005, 86:611-621.
74. Vogt M., Butz K., Dymalla S., Semzow J., Hoppe-Seyler F. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 2006, 25:4009-4015.
75. Duerksen-Hughes P.J., Yang J., Schwartz S.B. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 1999, 264:55-65.
76. Filippova M., Parkhurst L., Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 2004, 279:25729-25744.
77. Yuan H., Fu F., Zhuo J., Wang W., Nishitani J., An D.S., Chen I.S., Liu X. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 2005, 24:5069-5078.
78. Branca M., Ciotti M., Giorgi C., Santini D., Di Bonito L., Costa S., Benedetto A., Bonifacio D., Di Bonito P., Paba P., Accardi L., Syrjänen S., Favalli C., Syrjänen K. HPV-PathogenISS Study Group, Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 130:223-231.
79. Samarawardana P., Dehn D.L., Singh M., Franquemont D., Thompson C., Gaido L., Torkko K.C., Homer P., Burke S., Titmus M.A., Nayi V., Shroyer K.R. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010, 118:146-156.
80. Zhang H.S., Postigo A.A., Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999, 97:53-61.
81. McLaughlin-Drubin M.E., Huh K.W., Münger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 2008, 82:8695-8705.
82. McLaughlin-Drubin M.E., Crum C.P., Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. USA 2011, 108:2130-2135.
83. Trimarchi J.M., Fairchild B., Wen J., Lees J.A. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc. Natl. Acad. Sci. USA 2001, 98:1519-1524.
84. Kim R.H., Kang M.K., Shin K.H., Oo Z.M., Han T., Baluda M.A., Park N.H. Bmi-1 cooperates with human papillomavirus type 16 E6 to immortalize normal human oral keratinocytes. Exp. Cell Res. 2007, 313:462-472.
85. Lee H.Y., Dohi D.F., Kim Y.H., Walsh G.L., Consoli U., Andreeff M., Dawson M.I., Hong W.K., Kurie J.M. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J. Clin. Invest. 1998, 101:1012-1019.
86. Baudino T.A., Maclean K.H., Brennan J., Parganas E., Yang C., Aslanian A., Lees J.A., Sherr C.J., Roussel M.F., Cleveland J.L. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol. Cell. 2003, 11:905-914.
87. Pelengaris S., Khan M. The many faces of c-MYC. Arch. Biochem. Biophys. 2003, 416:129-136.
88. Secombe J., Pierce S.B., Eisenman R.N. Myc: a weapon of mass destruction. Cell 2004, 117:153-156.
89. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
90. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
91. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537.
92. Balsitis S., Dick F., Lee D., Farrell L., Hyde R.K., Griep A.E., Dyson N., Lambert P.F. Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J. Virol. 2005, 79:11392-11402.